Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enliven Therapeutics (ELVN) Profit After Tax (2019 - 2026)

Enliven Therapeutics has reported Profit After Tax over the past 8 years, most recently at -$23.6 million for Q1 2026.

  • Quarterly results put Profit After Tax at -$23.6 million for Q1 2026, up 17.23% from a year ago — trailing twelve months through Mar 2026 was -$98.8 million (down 4.16% YoY), and the annual figure for FY2025 was -$103.7 million, down 16.48%.
  • Profit After Tax reached -$23.6 million in Q1 2026 per ELVN's latest filing, up from -$29.7 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$8.7 million in Q1 2022 and bottomed at -$29.7 million in Q4 2025.
  • Median Profit After Tax over the past 5 years was -$20.1 million (2025), compared with a mean of -$19.2 million.
  • The largest annual shift saw Profit After Tax surged 33.31% in 2022 before it tumbled 102.83% in 2023.
  • Over 5 years, Profit After Tax stood at -$9.5 million in 2022, then tumbled by 102.83% to -$19.4 million in 2023, then decreased by 19.67% to -$23.2 million in 2024, then fell by 27.99% to -$29.7 million in 2025, then increased by 20.36% to -$23.6 million in 2026.
  • Business Quant data shows Profit After Tax for ELVN at -$23.6 million in Q1 2026, -$29.7 million in Q4 2025, and -$20.1 million in Q3 2025.